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Cardioprotection in Pigs by Exogenous Norepinephrine but
not by Cerebral Ischemia–Induced Release of
Endogenous Norepinephrine
Sandra de Zeeuw, PhD; Thomas W. Lameris, MD; Dirk J. Duncker, MD, PhD; Djo Hasan, MD, PhD;
Frans Boomsma, PhD; Anton H. van den Meiracker, MD, PhD; Pieter D. Verdouw, PhD
Background and Purpose—Endogenous norepinephrine release induced by cerebral ischemia may lead to small areas of
necrosis in normal hearts. Conversely, norepinephrine may be one of the mediators that limit myocardial infarct size by
ischemic preconditioning. Because brief ischemia in kidneys or skeletal muscle limits infarct size produced by coronary
artery occlusion, we investigated whether cardiac norepinephrine release during transient cerebral ischemia also elicits
remote myocardial preconditioning.
Methods—Forty-one crossbred pigs of either sex were assigned to 1 of 7 experimental groups, of which in 6 groups
myocardial infarct size was determined after a 60-minute coronary occlusion and 120 minutes of reperfusion. One group
served as control (no pretreatment), while the other groups were pretreated with either cerebral ischemia or an
intracoronary infusion of norepinephrine.
Results—In 10 anesthetized control pigs, infarct size was 8463% (mean6SEM) of the area at risk after a 60-minute
coronary occlusion and 120 minutes of reperfusion. Intracoronary infusion of 0.03 nmol/kg · min21 norepinephrine for
10 minutes before coronary occlusion did not affect infarct size (8063%; n56), whereas infusion of 0.12 nmol/kg ·
min21 limited infarct size (6562%; n57; P,0.05). Neither 10-minute (n55) nor 30-minute (n56) cerebral ischemia
produced by elevation of intracranial pressure before coronary occlusion affected infarct size (8364% and 8263%,
respectively). Myocardial interstitial norepinephrine levels tripled during cerebral ischemia and during low-dose
norepinephrine but increased 10-fold during high-dose norepinephrine. Norepinephrine levels increased progressively
up to 500-fold in the area at risk during the 60-minute coronary occlusion, independent of the pretreatment, while
norepinephrine levels remained unchanged in adjacent nonischemic myocardium and arterial plasma.
Conclusions—Cerebral ischemia preceding a coronary occlusion did not modify infarct size, which is likely related to the
modest increase in myocardial norepinephrine levels during cerebral ischemia. The infarct size limitation by high-dose
exogenous norepinephrine is not associated with blunting of the ischemia-induced increase in myocardial interstitial
norepinephrine levels. (Stroke. 2001;32:767-774.)
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Ischemic preconditioning, originally described for the myo-cardium,1 also occurs in kidney,2 skeletal muscle,3 lung,4
and brain.5 Przyklenk et al6 showed that brief regional
myocardial ischemia protects not only the jeopardized myo-
cardium during a subsequent coronary artery occlusion but
also the adjacent “virgin” myocardium. Furthermore, it has
been shown that brief ischemia in remote organs such as
kidney,7 small intestine,7 and skeletal muscle8 is also capable
of limiting myocardial infarct size produced by a prolonged
coronary artery occlusion. Norepinephrine is one of the
mediators involved in the signaling pathway leading to
ischemic preconditioning,9,10 and because cerebral ischemia
causes a profound release of norepinephrine from sympa-
thetic nerve endings in normal myocardium,11 this raises the
question of whether transient cerebral ischemia before a
coronary artery occlusion may also be cardioprotective. In
addition, exogenous administration of norepinephrine before a
coronary artery occlusion elicits cardioprotection in rabbits12 and
rats.13 The major aim of this study was therefore to investigate
the effect of cerebral ischemia on myocardial infarct size
produced by a coronary artery occlusion in pigs. Because the
cardioprotective effect of norepinephrine has not been estab-
lished in pigs, we first studied whether intracoronary infusions of
norepinephrine are capable of limiting myocardial infarct size.
An additional aim was, with the use of microdialysis,11,14 to
quantify the myocardial norepinephrine concentrations during
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cerebral ischemia and exogenous norepinephrine infusions and
to determine whether limitation of infarct size is mediated by
attenuation of myocardial interstitial norepinephrine levels dur-
ing the infarct-producing coronary artery occlusion.15
Materials and Methods
The present experiments were performed to conform with the Guide
for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH publication No. 85-23, revised
1996) and under the regulations of Erasmus University Rotterdam.
Experimental Groups
Forty-one crossbred Landrace3Yorkshire pigs of either sex (weight,
3461 kg) were assigned to 1 of 7 experimental groups, of which in
6 groups myocardial infarct size was determined at the end of the
protocol (Figure 1). Ten animals (control) underwent a 60-minute
left anterior descending coronary artery (LAD) occlusion followed
by 120-minute reperfusion, while in 13 animals the 60-minute LAD
occlusion/reperfusion was preceded by a 10-minute norepinephrine
infusion into the LAD at a rate of either 0.03 nmol/kg · min21 (NElow,
n56) or 0.12 nmol/kg · min21 (NEhigh, n57). In 3 animals, the effects
of the 10-minute high-dose norepinephrine infusion (NEhigh sham) on
myocardial function and metabolism were evaluated to assess
whether this dose produced myocardial ischemia and asynchrony of
contraction. Infarct size was not determined in these animals. In 5
animals a 10-minute period of global cerebral ischemia (CI10)
preceded the 60-minute LAD occlusion by 20 minutes, while in 6
animals the LAD occlusion was preceded by a 30-minute period of
cerebral ischemia (CI30) and 30 minutes of reperfusion. Finally, in 4
animals we studied whether 30 minutes of global cerebral ischemia
per se (CI30 sham) damaged normal myocardium. Cerebral ischemia
was achieved by infusion of artificial cerebrospinal fluid,16 such that
intracranial pressure increased to approximately 250 mm Hg (invari-
ably above the systolic arterial pressure). In all groups, a 120-minute
stabilization period followed the surgical procedures, after which
baseline measurements were made. Microdialysis was performed in
control, NElow, NEhigh, and CI30 groups. Dialysate samples were
collected over 10-minute periods for determination of myocardial
interstitial norepinephrine concentrations starting 90 minutes into the
stabilization period, when norepinephrine concentrations had
reached stable levels.14,15 During the subsequent 30 minutes, base-
line dialysate samples were collected. Plasma samples were obtained
halfway through each 10-minute dialysate collection period. Animals
encountering ventricular fibrillation during the protocol were al-
lowed to complete the experiment when sinus rhythm could be
restored by direct current countershock within 2 minutes.
Surgery
Overnight fasted pigs were sedated with ketamine (20 to 25 mg/kg
IM; Apharmo), anesthetized with sodium pentobarbital (20 mg/kg
IV; Apharmo), and intubated for ventilation with 30% oxygenated
room air, while arterial blood gases were kept within the normal
range. Catheters were inserted into the superior caval vein for
infusion of sodium pentobarbital (10 to 15 mg/kg · h21) and saline.
A fluid-filled catheter was placed in the descending aorta for
measurement of aortic blood pressure and collection of blood
samples, while a micromanometer-tipped catheter was inserted in the
carotid artery and advanced into the left ventricle for measurement of
left ventricular pressure (LVP) and its first derivative (LVdP/dt).
After administration of pancuronium bromide (4 mg; Organon
Teknika BV) and a midsternal thoracotomy, the heart was suspended
in a pericardial cradle. An electromagnetic flow probe (Skalar) was
placed around the ascending aorta for measurement of cardiac
output, while the segment of the LAD between the first and the
second diagonal branch was dissected free for placement of a
Doppler flow probe (Triton Technology Inc) and a microvascular
clamp. In NElow, NEhigh, and NEhigh sham groups, a small cannula was
inserted into the LAD distal to the flow probe.
One microdialysis probe was implanted in the LAD area and one
in the left circumflex coronary artery (LCx) area. In CI30, a third
probe was placed in the cortex of the brain. Perfusion of the probes
started immediately after insertion.14,15
In CI30 sham and NEhigh sham groups, pairs of ultrasound crystals were
implanted in the midmyocardial layer of the LAD and LCx areas to
assess regional myocardial wall function (Triton Technology Inc),
while the great cardiac vein accompanying the LAD was cannulated
for collection of blood samples. Finally, in the NEhigh sham group, the
left atrium was also cannulated for injection of radioactive micro-
spheres (113Sn or 141Ce, 1561 [SD] mm) to determine the effect of
norepinephrine on the distribution of myocardial blood flow.1
Two catheters were inserted into the left and right cerebral lateral
ventricles through bore holes to produce cerebral ischemia.17 A
fluid-filled catheter was used for infusion of the artificial cerebro-
spinal fluid to elevate intracranial pressure, which was monitored
with a micromanometer-tipped catheter.
Microdialysis
The polycarbonate dialysis membrane of the microdialysis probes
(CMA/20, Carnegie Medicine) has a cutoff value of 20 kDa, a length
of 10 mm, and a diameter of 0.5 mm. Cardiac probes were perfused
with an isotonic Ringer’s solution, and the cerebral probe was
perfused with the artificial cerebrospinal fluid at a rate of 2 mL/min
with the use of a CMA/100 microinjection pump. Dialysate volumes
of 20 mL (sampling time 10 minutes) were collected in microvials
containing 20 mL of a solution of 2% (wt/vol) EDTA and 30 nmol/L
l-erythro-a-methyl-norepinephrine as internal standard in 0.08N
acetic acid. Plasma samples were drawn into chilled heparinized
tubes containing 12 mg glutathione. All samples were stored at
280°C until analysis within the next 5 days.14,15 In vivo probe
recovery of norepinephrine, determined by retrodialysis and by
direct comparison of hemomicrodialysis and plasma samples, is
5261%.14,15,18
Infarct Size
At the end of the 120-minute reperfusion period, the area at risk was
determined by intra-atrial infusion of 20 mL of 5% (wt/wt) fluores-
cein sodium.19 After the heart was excised, the left ventricle was
isolated and cut parallel to the atrioventricular groove into 5 slices of
equal thickness. After the area at risk of each slice was demarcated
on an acetate sheet under ultraviolet light, the slices were incubated
in 0.125 g para-nitroblue tetrazolium (Sigma Chemical Co) per liter
of phosphate buffer (pH 7.4) at 37°C for 30 minutes, and the
nonstained pale infarcted area was also traced onto the sheet.
Figure 1. Seven experimental groups. Norepinephrine (NE) was
infused at a rate of either 0.03 (NElow) or 0.12 nmol/kg · min21
(NEhigh and NEhigh sham) into the LAD. Global cerebral ischemia
(CI), produced by elevating intracranial pressure (ICP), was
maintained for either 10 minutes (CI10) or 30 minutes (CI30 and
CI30 sham). Infarct size was determined at the end of 120 minutes
of reperfusion in all groups except in NEhigh sham.
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Myocardial infarct size was defined as the ratio of the summed
infarct areas and summed areas at risk.19
Regional Myocardial Function and Perfusion
Percent systolic shortening (SS) was calculated as the difference in
segment length at end diastole and the minimal segment length
during systole divided by the segment length at end diastole.
Asynchrony during norepinephrine infusion was assessed by deter-
mining the time interval between the occurrence of minimal segment
length (Lmin) in the LAD and LCx areas.
Myocardial O2 extraction (%) was calculated as the ratio of the
arterio–coronary venous O2 content difference and the arterial O2
content. At the end of the experiment, the heart was excised, and the
LAD and LCx areas were separated and divided into 3 layers of
equal thickness to determine the subendocardial (inner layer) and
subepicardial (outer layer) blood flows and their ratios, with the use
of standard techniques.1
Statistical Analysis
All data have been expressed as mean6SEM. Statistical significance
(P,0.05) for changes in hemodynamics and norepinephrine concen-
trations was determined by 2-way ANOVA and 1-way ANOVA for
repeated measures, followed by Dunnett’s multiple comparison test.
Statistical significance (P,0.05) for differences in infarct size was
determined by 1-way ANOVA followed by Student’s t test.
Results
Hemodynamics
Norepinephrine Infusions
Intracoronary norepinephrine infusion in the NElow group
produced an increase in maximal rise in LVP (LVdP/dtmax),
reflecting an increase in regional contractility as the other
cardiovascular variables remained unaffected (Table 1). Dur-
ing the 10-minute washout period, LVdP/dtmax returned
to baseline. During norepinephrine infusion in NEhigh and
NEhigh sham groups, mean arterial pressure decreased rapidly
from 9162 to 7466 mm Hg, followed by a gradual recovery
(Table 1). The decrease in cardiac output was responsible for
the hypotension as systemic vascular resistance remained
unchanged. Cardiac output decreased because the increase in
heart rate was insufficient to compensate for the decrease in
stroke volume. The latter occurred despite the increase
in LVdP/dtmax and was likely due to asynchrony of contrac-
tion (see below). All parameters recovered during the 10-
minute washout period that preceded the 60-minute LAD
occlusion.
During norepinephrine infusion in the NEhigh sham group, SS
in the LAD area increased from 2762% at baseline to
3464%, while SS in the LCx area decreased from 1861% to
1361% (both P,0.05). These changes were accompanied by
asynchrony of contraction between the LAD and LCx areas.
Thus, whereas under baseline conditions Lmin of both areas
occurred at the end of global left ventricular systole, during
norepinephrine infusion the occurrence of Lmin in the LAD
area preceded Lmin in the LCx area by 11962 ms (P,0.05).
The latter was due to Lmin in the LAD area occurring 56615
ms before and Lmin in the LCx area occurring 6367 ms after
closure of the aortic valves (both P,0.05 versus their
respective baseline values). During washout, all wall function
parameters returned to baseline values.
In the LAD area of NEhigh sham, O2 extraction decreased from
6467% at baseline to 5467% during norepinephrine infu-
sion, indicating that O2 delivery increased slightly in excess
of the increase in myocardial O2 demand. In addition, the
arterio–coronary venous pH difference remained unchanged
(0.0660.01 at baseline and at the end of infusion). Moreover,
the subendocardial to subepicardial blood flow ratio remained
unchanged in both the LAD area (1.1460.25 at baseline and
1.3060.17 at the end of infusion) and the LCx area
(1.2160.07 and 1.2460.05, respectively). Finally, SS in the
LAD and LCx areas returned to baseline values immediately
during the recovery period (2463% and 1761%, respective-
ly), indicating that the norepinephrine infusion did not pro-
duce myocardial ischemia and stunning.
Cerebral Ischemia
Increasing intracranial pressure (1262 mm Hg at baseline) to
250 mm Hg produced an immediate increase in mean aortic
pressure in CI10, CI30, and CI30 sham groups, which was initially
the consequence of increases in both cardiac output and
systemic vascular resistance (Table 1). However, after 5
minutes the tachycardia-mediated increase in cardiac output
was exclusively responsible for the hypertension. Despite the
increase in afterload, stroke volume was maintained, most
likely because of enhanced myocardial contractility as LVdP/
dtmax increased up to 4 times its baseline value. The increase
in coronary blood flow paralleled the increase in myocardial
O2 demand, reflected by the 150% increase in double product
(heart rate3systolic arterial pressure).
Similar to earlier observations in dogs20 and pigs,11 the
transient hyperdynamic phase was followed by a fall in mean
arterial pressure below baseline levels at 10 minutes of
cerebral ischemia, which was the result of systemic vasodi-
latation. Except heart rate, which remained slightly elevated,
all other variables had recovered at 10 minutes. In CI30 and
CI30 sham groups, mean arterial pressure, cardiac output, and
systemic vascular resistance did not change further during the
remainder of the 30-minute period of cerebral ischemia, while
heart rate returned to baseline levels and stroke volume
increased. Except for mean arterial pressure and systemic
vascular resistance, all other hemodynamic variables and
intracranial pressure returned to baseline values during recov-
ery (Table 1).
The increase in intracranial pressure decreased myocardial
O2 extraction from 6465% at baseline to 5866% at 5
minutes but did not change the arterio–coronary venous pH
difference (0.0460.01 at baseline and at 5 minutes), indicat-
ing the absence of myocardial ischemia. The elevation of
intracranial pressure decreased SS from 2461% to 1662% at
2 minutes, but SS had already recovered to 2361% at 5
minutes and to 2661% at 10 minutes, with no evidence of
depressed regional wall function during the remainder of the
30-minute period (2761%) or the subsequent recovery phase
(2363%).
LAD Occlusion and Reperfusion
In the control group, mean arterial pressure decreased sec-
ondary to the decrease in cardiac output during the 60-minute
LAD occlusion and did not change further during reperfusion
(Table 2). Heart rate increased slightly, but insufficiently to
compensate for the decrease in stroke volume.
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Pretreatment with norepinephrine had no effect on the
hemodynamic responses during the subsequent LAD occlu-
sion and reperfusion in either NElow or NEhigh. In CI10 and CI30
groups, mean arterial pressure did not further decrease during
the LAD occlusion, most likely because systemic vascular
resistance, which was still below baseline levels at the onset
of LAD occlusion, recovered.
Myocardial Infarct Size
The area at risk was identical in all experimental groups
(Figure 2). Infarct size was 8463% in control and 8063% in
NElow groups but only 6562% in the NEhigh group (P,0.05).
Cerebral ischemia had no effect on infarct size development
during the 60-minute LAD occlusion, since in CI10 and CI30
groups infarct size was 8364% and 8263%, respectively.
Cerebral ischemia per se did not cause irreversible damage,
since in none of the CI30 sham animals was infarct tissue
detected.
Myocardial Interstitial
Norepinephrine Concentrations
The myocardial interstitial norepinephrine levels in the LAD
area increased from 0.860.2 to 2.260.5 nmol/L in the NElow
group and to 12.265.9 nmol/L in the NEhigh group during
norepinephrine infusion (both P,0.05; Figure 3). Despite the
intracoronary route, there was some spillover in the NEhigh
group, as evidenced by small transient increments of norepi-
nephrine in plasma from 0.260.1 to 1.060.2 nmol/L and in
the interstitium of the LCx area from 1.160.3 to 2.461.2
nmol/L (both P,0.05; Figure 3).
In CI30, cerebral interstitial norepinephrine levels increased
from 0.960.4 nmol/L at baseline to 6.161.9 nmol/L at 10
TABLE 1. Cardiovascular Hemodynamics During Norepinephrine Infusion or Cerebral Ischemia
Treatment Baseline
D From Baseline
2 min 5 min 10 min 30 min Recovery
Mean arterial pressure, mm Hg NElow 9363 063 262 363 z z z 2162
NEhigh1NEhigh sham 9162 21566* 21765* 2864 z z z 2262
CI10 9265 80610* 53613* 21165 z z z 216612
CI301CI30 sham 9064 8366* 6768* 21964* 21765* 22064*
Cardiac output, L z min21 NElow 2.960.2 0.060.1 0.060.1 0.060.1 z z z 20.160.1
NEhigh1NEhigh sham 2.560.2 20.460.2* 20.560.2* 20.260.1 z z z 20.160.1
CI10 3.860.5 0.760.2* 2.160.4* 0.760.3 z z z 20.360.6
CI301CI30 sham 3.160.2 0.760.2* 2.260.3* 0.460.1* 0.960.2* 20.260.4
Systemic vascular resistance, NElow 3363 0.260.8 0.460.7 1.160.7 z z z 1.161.1
mm Hg/L z min21 NEhigh1NEhigh sham 3763 20.661.4 0.760.9 0.661.0 z z z 1.260.9
CI10 2663 15.964.6* 1.464.4 27.461.9* z z z 23.661.0*
CI301CI30 sham 3062 18.864.2* 1.863.2 28.861.3* 211.061.5* 29.062.1*
Heart rate, bpm NElow 10767 161 162 162 z z z 163
NEhigh1NEhigh sham 11766 1364* 1565* 1265* z z z 262
CI10 11265 3768* 68612* 19613 z z z 17610
CI301CI30 sham 10163 4665* 7966* 2264* 263 967
Stroke volume, mL NElow 2764 1.161.5 1.561.4 1.261.2 z z z 0.561.1
NEhigh1NEhigh sham 2262 25.461.9* 26.461.6* 23.861.7 z z z 21.160.7
CI10 3363 22.662.2 0.263.8 1.463.0 z z z 25.863.0
CI301CI30 sham 3062 24.461.8* 20.861.5 21.861.2 8.061.6* 24.263.2
LVdP/dtmax, mm Hg z s21 NElow 15606110 7606100* 790690* 850660* z z z 260670
NEhigh1NEhigh sham 20306200 8606210* 8906160* 12706120* z z z 2150670
CI–10 17906170 28106660* 46506910* 23106410 z z z 4106560
CI301CI30 sham 16406120 25706440* 50106340* 1606230 2906170 506220
Left ventricular end-diastolic NElow 862 1.260.5 1.360.6 1.960.8 z z z 1.160.6
pressure, mm Hg NEhigh1NEhigh sham 861 21.760.8 22.060.8* 21.460.6 z z z 0.760.6
CI10 961 8.561.7* 1.561.2 0.262.4 z z z 22.561.8
CI301CI30 sham 761 10.662.5* 0.961.7 21.261.2 1.861.5 0.060.9
Coronary blood flow, mL/min z g21 NElow 1.760.2 0.360.2 0.360.2 0.360.1 z z z 0.060.2
NEhigh1NEhigh sham 1.060.1 0.060.1 0.160.1 0.360.1 z z z 0.060.1
CI10 1.060.2 1.060.2* 0.760.1* 0.060.1 z z z 20.160.1
CI301CI30 sham 1.360.1 1.360.2* 1.460.3* 20.160.1 0.260.2 20.160.1
Data are mean6SEM; n56 (NElow), n510 (NEhigh1NEhigh sham), n55 (CI10), n510 (CI301CI30 sham).
*P,0.05 vs baseline.
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minutes of intracranial pressure elevation and up to 8.361.8
nmol/L at 30 minutes (not shown in Figure 3). On cerebral
reperfusion, interstitial levels initially increased further to
12.362.3 nmol/L but returned to baseline during the remain-
der of the 30-minute recovery period. Cerebral ischemia
resulted in a transient tripling of interstitial norepinephrine
levels in both the LAD and LCx areas and in a 20-fold
increase in plasma norepinephrine levels (Figure 3).
In control, NElow, NEhigh, and CI30 groups, norepinephrine
levels increased progressively during LAD occlusion by up to
approximately 500-fold and recovered during reperfusion,
independent of the preceding intervention (Figure 4). There
was no correlation (r50.03) between the maximum intersti-
tial norepinephrine levels during LAD occlusion and myo-
cardial infarct size.
Discussion
The major findings of the present study are as follows: (1)
global cerebral ischemia, produced by either a 10-minute or a
30-minute elevation of intracranial pressure, which by itself
produced no irreversible myocardial damage, had no effect on
myocardial infarct size produced by 60-minute coronary
artery occlusion; (2) intracoronary infusion of 0.03 nmol/kg ·
min21 norepinephrine produced increases in myocardial in-
TABLE 2. Cardiovascular Hemodynamics During Coronary Occlusion and Reperfusion
Treatment
Preocclusion
Values
End-Occlusion
Values
End-Reperfusion
Values
Mean arterial pressure, mm Hg Control 9062 7562* 7666*
NElow 9364 7266* 7065*
NEhigh 8764 7765 7764
CI10 7569 7465 6565
CI30 6564 6165 6664
Cardiac output, L z min21 Control 2.660.2 2.160.1* 2.160.2*
NElow 2.860.2 2.360.2* 1.960.1*
NEhigh 2.260.2 1.960.2* 1.860.2*
CI10 3.560.4 2.960.3 2.560.4
CI30 2.960.3 2.260.2* 2.060.1*
Systemic vascular resistance, Control 3863 3763 3864
mm Hg/L z min21 NElow 3464 3263 3864
NEhigh 4164 4364 4565
CI10 2263 2764 2864*
CI30 2462 2862* 3362*
Heart rate, bpm Control 11564 12367 13968*
NElow 10869 11269 119613
NEhigh 12466 133611 136611
CI10 12967 11969 12067
CI30 11266 11265 11566
Stroke volume, mL Control 2262 1861* 1661*
NElow 2764 2263 1762
NEhigh 1862 1462* 1361*
CI10 2864 2564 2163
CI30 2562 2062* 1861*
LVdP/dtmax, mm Hg z s21 Control 16106100 14806100 16406260
NElow 15006110 13506110 12506100
NEhigh 19806280 20606350 20506340
CI10 22006410 16306140 13506140
CI30 17106320 12506160 11706100
Left ventricular end-diastolic pressure, Control 761 961 1061*
mm Hg NElow 962 1061 1061
NEhigh 862 1062 1261
CI10 763 1363 1361
CI30 661 962* 1261*
Data are mean6SEM; n510 (control), n56 (NElow), n57 (NEhigh), n55 (CI10), n56 (CI30). Preocclusion values of the norepinephrine
and cerebral ischemia groups correspond to the recovery values in Table 1.
*P,0.05 vs preocclusion values.
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terstitial levels similar to those produced by cerebral ischemia
and also did not limit myocardial infarct size; (3) conversely,
intracoronary infusion of 0.12 nmol/kg · min21 of norepineph-
rine, which resulted in 5-fold higher myocardial interstitial
norepinephrine levels than cerebral ischemia and low-dose
norepinephrine, was capable of limiting myocardial infarct
size; (4) the cardioprotection by exogenous norepinephrine
was not caused by ischemic preconditioning; and (5) this
protection was not associated with a blunting of the progres-
sive increase in myocardial interstitial norepinephrine levels
during coronary artery occlusion.
Catecholamines and Myocardial Injury
The relation between catecholamines and myocardial injury
was first established by Rona and coworkers,21,22 who
showed some 40 years ago that administration of high
systemic doses of isoproterenol produced focal necrotic
lesions in normal rat hearts.
Elevation of intracranial pressure is well recognized as a cause
of myocardial dysfunction and injury. Brain death caused by
increased intracranial pressure produces echocardiographic al-
terations, hemodynamic instability, and contraction band necro-
sis, all of which have been suggested to be the result of massive
neuronal depolarization and release of catecholamines.23–25
These clinical observations initiated a large number of experi-
mental investigations in which deleterious effects of brain death
on function and integrity of normal myocardium were found, but
generally no or only minimal focal myocardial necrosis could be
demonstrated.26,27
In view of the massive myocardial norepinephrine release
during coronary artery occlusion,15,28 it could be hypothe-
sized that catecholamines may contribute to the development
of irreversible injury during a coronary artery occlusion.
Several,29,30 although certainly not all,31,32 studies have re-
ported that b-adrenoceptor blockade slows the development
of myocardial infarction. In contrast, depletion of cardiac
norepinephrine stores by reserpination did not limit myocar-
dial infarct size in rabbits9 and dogs,10 suggesting that
endogenous catecholamines do not contribute to irreversible
damage.
In contrast to the potentially deleterious effects of norepi-
nephrine on normal and ischemic myocardium, this catechol-
amine has also been implicated in mediating cardioprotection
by ischemic preconditioning. Thus, Toombs et al9 showed
that in rabbits the protection by ischemic preconditioning was
abolished when catecholamine stores in sympathetic nerve
endings were depleted by reserpine. Furthermore, Thornton et
al12 demonstrated in the same species that tyramine-induced
norepinephrine release 10 minutes before a 30-minute coro-
nary artery occlusion also protected the myocardium. This
cardioprotective action of catecholamines has been confirmed
in other species such as the rat13 and the dog.10 We now show
that a high dose of norepinephrine can also protect the
porcine myocardium.
Our data on wall function, myocardial blood flow, O2
extraction, and proton release indicate that the high dose of
norepinephrine did not produce myocardial ischemia and
therefore did not protect the myocardium by ischemic pre-
conditioning. The degree of protection afforded by norepi-
nephrine is less than reported for ischemic preconditioning
but similar to that produced by other nonischemic stimuli,
such as ventricular pacing33 and pharmacological agents such
as the K1ATP channel openers.34 Since all these stimuli have in
common that they ultimately activate K1ATP channels, it is
tempting to speculate that norepinephrine also protected via
a1-adrenoceptor–mediated protein kinase C activation and
subsequent opening of (mitochondrial) K1ATP channels.35
Another mechanism by which norepinephrine might protect
the myocardium is via a blunted release in catecholamines
during the sustained ischemic episode.36 However, pretreat-
ment with norepinephrine did not modify the release of
cardiac norepinephrine during sustained myocardial ischemia
in the present study, implying that the norepinephrine-
mediated cardioprotection is not related to a blunting of the
ischemia-induced increase in norepinephrine levels.
Figure 2. Area at risk and infarct size for the 5 experimental
groups in which the LAD was occluded for 60 minutes and
reperfused for 120 minutes. Global cerebral ischemia alone
(CI30 sham) did not cause irreversible myocardial damage (not
shown). *P,0.05 vs control. For further details see Figure 1.
Figure 3. Norepinephrine levels in plasma and
in the interstitium of the LAD area and the LCx
area during the 10-minute norepinephrine infu-
sions and during 30 minutes of cerebral ische-
mia. *P,0.05 vs baseline. For further details
see Figure 1.
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Finally, the present study clarifies another issue on the role
of norepinephrine in cardioprotection. Przyklenk et al6 dem-
onstrated that myocardial ischemia also elicited cardioprotec-
tion in adjacent virgin myocardium and speculated that this
might have been triggered by a substantial catecholamine
release in that adjacent region. However, we now show that
norepinephrine levels in the normal (LCx-perfused) myocar-
dium remained unaltered during and after the 60-minute LAD
occlusion (Figure 4), even though the interstitial norepineph-
rine levels in the LAD area were 100-fold higher than the
value observed after 10 minutes of ischemia, corresponding
to the period used by Przyklenk et al6 to precondition the
adjacent virgin myocardium.
Cerebral Ischemia as a Stimulus
for Cardioprotection
Transient ischemia in small intestines, kidneys, and skeletal
muscle before a coronary artery occlusion can also be
cardioprotective.7,8 We therefore hypothesized that cerebral
ischemia might similarly protect the myocardium, especially
because cerebral ischemia is associated with substantial
norepinephrine release, one of the mediators involved in
cardioprotection by ischemic preconditioning. However, tran-
sient cerebral ischemia did not reduce myocardial infarct size
in the present study. The explanation for the lack of protec-
tion might be 2-fold. First, 30 minutes of cerebral ischemia
did not produce myocardial ischemia and could therefore not
protect the myocardium via ischemic preconditioning. Sec-
ond, although myocardial interstitial norepinephrine levels
increased during cerebral ischemia, the rise was much less
than during infusion of the high dose of norepinephrine,
which elicited cardioprotection. This is further corroborated
by our findings with the low dose of norepinephrine, which
produced interstitial myocardial norepinephrine levels similar
to those produced by cerebral ischemia and was also ineffec-
tive in protecting the heart.
It could be argued that even the 30-minute global cerebral
ischemia (CI30) was too short to elicit cardioprotection.
However, there is ample evidence that the intensity of the
preconditioning stimulus is more important than its dura-
tion.37 Moreover, because the elevation of myocardial inter-
stitial norepinephrine levels occurred exclusively during the
first 10 minutes of cerebral ischemia, it is unlikely that
extending the period of cerebral ischemia would produce
cardioprotection. On the contrary, it might be argued that the
duration of the intracranial pressure elevation and recovery
phase lasted too long since the maximum myocardial inter-
stitial norepinephrine levels reached their peak during the
first 10 minutes, so that a potential effect of that stimulus was
lost by the time (50 minutes later) the LAD was occluded.
This is supported by observations that the memory for
cardioprotection is shorter when stimuli are used that do not
cause myocardial ischemia.33,34 However, when cerebral
ischemia was maintained for only 10 minutes and cerebral
reperfusion was shortened to 20 minutes (CI10), infarct size
after the 60-minute coronary artery occlusion was also not
different from control.
Finally, it can be excluded that a protective effect of
transient global cerebral ischemia during LAD occlusion was
masked by irreversible myocardial damage produced by
transient global cerebral ischemia before LAD occlusion,
since irreversible damage could not be detected in the animals
subjected to only 30 minutes of cerebral ischemia (CI30 sham).
This observation is in agreement with most experimental
studies that have generally reported minimal or no focal
myocardial necrosis after cerebral ischemia.26,27
Conclusions
In conclusion, global cerebral ischemia preceding a coronary
artery occlusion did not modify myocardial infarct size,
which is likely related to the modest increase in myocardial
norepinephrine levels during cerebral ischemia. The infarct
size limitation by the high dose of norepinephrine was not
associated with a blunting of the increase in myocardial
interstitial norepinephrine levels during coronary occlusion.
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